HB002.1T / Zhejiang Huahai Pharma - LARVOL DELTA

Pseudomonas algeriensis sp. nov.: A Promising Phosphate-Solubilizing Endophytic Bacterium Isolated from Legume Root Nodules in the Coastal Dunes of Northwest Algeria. (PubMed, Curr Microbiol) - "Analysis of the 16S rRNA gene sequence revealed that strain NR3T shared the highest pairwise sequence similarity with Pseudomonas canavaninivorans HB002T (99.6%), Pseudomonas alvandae SWRI17T (99.5%), Pseudomonas bijieensis L22-9T (99.5%), and Pseudomonas tehranensis SWRI196T (99.4%)...nov. is proposed."

Journal • Infectious Disease

A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors. (ASCO 2023) - P1 | " This study aimed to evaluate efficacy and safety of HB002.1T plus chemotherapy (mainly based on platinum, paclitaxel, gemcitabine, etc.) in advanced solid tumors. The Pts were well tolerated to 12mg/kg and 16mg/kg HB002.1T dose combined with chemotherapy, and HB002.1T showed acceptable safety profile. As well as, promising anti-tumor activity was observed in various tumors, especially in advanced ovarian cancer. More data is being accumulated, and confirmatory clinical trials are being prepared."

Clinical • Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Renal Disease • Solid Tumor • VEGFB

Pseudomonas canavaninivorans sp. nov., isolated from bean rhizosphere. (PubMed, Int J Syst Evol Microbiol) - "is proposed. The type strain is HB002 (=DSM 112525=LMG 32336)."

Journal • CAT

[VIRTUAL] INTERIM RESULTS OF HBV001, A PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF THERAPEUTIC VACCINATION WITH ChAdOx1-HBV IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC HEPATITIS B INFECTION (AASLD 2021) - P1, P1b/2a | "Vaccination with ChAdOx1- HBV is well tolerated and induces T cell responses in healthy volunteers and patients with chronic HBV. A phase II study of ChAdOx1-HBV in combination with MVA-HBV and the anti- PD1 agent Nivolumab in patients with chronic HBV is ongoing (HBV002, NCT04778904)."

Clinical • P1 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pain • IFNG

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Huabo Biopharm Co., Ltd.; Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

Complete Genome Sequences of Thermus thermophilus Strains HB5002 and HB5008, Isolated from Mine Hot Spring in Japan. (PubMed, Microbiol Resour Announc) - "We isolated Thermus thermophilus strains HB5002 and HB5008 from Mine Hot Spring in Japan. Whole-genome sequencing revealed that they showed ∼100% average nucleotide identity to each other, ≥98.53% to the T. thermophilus strains originating from the same spot but ≤97.64% to the T. thermophilus strains from geographically different places in Japan."

Journal

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Huabo Biopharm Co., Ltd.

Clinical • Combination therapy • New P1 trial • Cholangiocarcinoma • Lung Cancer • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial completion date: Feb 2021 ➔ Aug 2021; Trial primary completion date: Feb 2021 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

[VIRTUAL] NEUROPROTECTION OF LOW DOSE CARBON MONOXIDE IN GENETIC AND TOXIN MODELS OF PARKINSON’S DISEASE (ADPD 2021) - "AAV-aSyn rats treated with HBI002 retained 74±12% (SD) of right striatal dopamine versus left, compared to 36±7% in vehicle-treated rats (p=0.03). Low-dose CO protects nigral dopamine neurons, preserves striatal dopamine content, and reduces aSyn pathology in animal models of PD. Low dose CO may have disease-modifying activity in PD."

CNS Disorders • Movement Disorders • Parkinson's Disease

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial completion date: Nov 2020 ➔ Feb 2021; Trial primary completion date: Oct 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Jun 2020 ➔ Nov 2020; Trial primary completion date: May 2020 ➔ Oct 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of Injection HB002.1T in Subjects With Solid Tumor (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Trial primary completion date: Aug 2019 ➔ May 2020

Clinical • Trial primary completion date